CASTLE ROCK, Colo., Sept. 22 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. , an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, announced today the company has accepted an invitation to present at the Noble Financial 2006 On Track Small Cap Conference. The conference will be held September 26, 27, & 28 at the Ballantyne Resort in Charlotte, North Carolina.
AspenBio Pharma president and CEO, Richard Donnelly, is scheduled to present on Tuesday, September 26th, at 1:15 pm EDT. A simultaneous Webcast and replay of the presentation will be available via this link: http://hosted.mediasite.com/hosted/viewer/?peid=f758780d-167a-4c1e-bb60- 3abc038ecc5d.
The Noble Financial Small Cap Conference will feature companies across a broad selection of industry sectors. Senior executives will make group presentations to analysts and portfolio managers on their business strategy and outlook, and will be available for breakout sessions and one-on-one meetings. For further information about the invitation-only conference, please visit: www.ontrack06.com/index.htm
About Noble Financial
Now in its 21st year, Noble Financial Group, Member NASD, SIPC, is a full-service capital markets firm driven by what is often overlooked by others -- a mission intent on uncovering the value embedded in the orphaned, undiscovered or misunderstood company. Noble Financial maintains a focus on converting market inefficiencies into profit opportunities and an uncompromising conviction for delivering a quality product. Noble Financial supports emerging growth companies through strategic advice, investment banking, market-making, sales and trading, comprehensive equity research, and the development of institutional support. For more information about Noble Financial, please visit: www.noblefinancialgroup.com.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and others that have large worldwide market potential. The company was formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation’s largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. The company has created an early pregnancy “open cow” diagnostic for dairy cows that is currently in late-stage development. AspenBio Pharma is also working on a blood test to assist in the diagnosis of appendicitis in humans. For more information, please visit: www.aspenbiopharma.com.
For more information contact: AspenBio Pharma, Inc. Richard Donnelly, CEO 303-794-2000 Investor Relations: Liolios Group, Inc. Scott Liolios or Ron Both 949-574-3860
AspenBio Pharma, Inc.
CONTACT: Richard Donnelly, CEO of AspenBio Pharma, Inc., +1-303-794-2000;or Investor Relations, Scott Liolios or Ron Both, both of Liolios Group,Inc., +1-949-574-3860, for AspenBio Pharma, Inc.
